Universal Beteiligungs und Servicegesellschaft mbH Makes New $392,000 Investment in Evolent Health, Inc (NYSE:EVH)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Evolent Health, purchasing 41,401 shares valued at approximately $392,000 during the first quarter.
• Other institutional investors also increased their stakes, with Allianz Asset Management lifting its holdings by 48.9% and Hussman Strategic Advisors raising its position by 66.7% in the same period.
• Evolent Health reported quarterly earnings of $0.06 per share, missing estimates, and had a revenue of $483.65 million, which was below the consensus estimate of $460.15 million.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Evolent Health, Inc (NYSE:EVH - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 41,401 shares of the technology company's stock, valued at approximately $392,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EVH. Allianz Asset Management GmbH increased its stake in Evolent Health by 48.9% in the 1st quarter. Allianz Asset Management GmbH now owns 68,541 shares of the technology company's stock worth $649,000 after acquiring an additional 22,514 shares during the last quarter. Hussman Strategic Advisors Inc. lifted its holdings in shares of Evolent Health by 66.7% in the 1st quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the technology company's stock worth $994,000 after buying an additional 42,000 shares during the period. Signaturefd LLC raised its position in shares of Evolent Health by 400.6% in the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock worth $67,000 after acquiring an additional 5,636 shares in the last quarter. Rock Point Advisors LLC increased its position in Evolent Health by 37.6% during the 1st quarter. Rock Point Advisors LLC now owns 824,535 shares of the technology company's stock valued at $7,808,000 after buying an additional 225,396 shares in the last quarter. Finally, 49 Wealth Management LLC acquired a new position in shares of Evolent Health in the first quarter valued at about $185,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EVH. JMP Securities reiterated a "market outperform" rating and set a $13.00 price target on shares of Evolent Health in a research report on Friday, June 20th. UBS Group lifted their price objective on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Truist Financial lifted their target price on Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price target on shares of Evolent Health in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $17.93.

Evolent Health Price Performance

Evolent Health stock traded up $0.22 during trading hours on Thursday, hitting $9.63. 835,665 shares of the stock were exchanged, compared to its average volume of 2,516,801. Evolent Health, Inc has a 12 month low of $7.06 and a 12 month high of $33.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.98 and a current ratio of 0.98. The business's 50-day moving average is $9.85 and its two-hundred day moving average is $9.65. The stock has a market capitalization of $1.13 billion, a P/E ratio of -7.81 and a beta of 0.82.

Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a positive return on equity of 3.64% and a negative net margin of 4.54%. The firm had revenue of $483.65 million during the quarter, compared to analyst estimates of $460.15 million. During the same quarter last year, the business posted $0.34 earnings per share. The company's revenue for the quarter was down 24.4% on a year-over-year basis. Equities research analysts expect that Evolent Health, Inc will post 0.08 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.